675590-04-2

Basic information

• Product Name: 3-BROMO-5-(4-FLUOROPHENYL)PYRIDINE
• Synonyms: 3-BROMO-5-(4-FLUOROPHENYL)PYRIDINE;3-Bromo-5(4-Fluorpphenyl)pyridine
• CAS NO: 675590-04-2
• Molecular Formula: C11H7BrFN
• Molecular Weight: 252.09
• Product Categories: Halides;Pyridines;Fluorine series
• Mol File: 675590-04-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 306°C at 760 mmHg
• Flash Point: 138.9°C
• Appearance: /
• Density: 1.497g/cm³
• Vapor Pressure: 0.00143mmHg at 25°C
• Refractive Index: 1.587
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-BROMO-5-(4-FLUOROPHENYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-(4-FLUOROPHENYL)PYRIDINE(675590-04-2)
• EPA Substance Registry System: 3-BROMO-5-(4-FLUOROPHENYL)PYRIDINE(675590-04-2)

Safety Data

• Hazardous Substances Data: 675590-04-2(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-(4-fluorophenyl)pyridine is a chemical compound with the molecular formula C11H7BrFN. It is a member of the pyridine family, which is commonly used in pharmaceutical and agrochemical synthesis. This particular compound contains a pyridine ring with a bromine atom at the 3-position and a 4-fluorophenyl group attached at the 5-position. It is primarily used as a building block in the synthesis of various organic compounds, including pharmaceuticals and agrochemicals. The presence of both a bromine and a fluorophenyl group makes this compound useful for creating complex molecules with specific chemical properties. 3-Bromo-5-(4-fluorophenyl)pyridine is typically handled and used by professionals in a laboratory setting due to its potential hazards and reactivity.

InChI:InChI=1/C11H7BrFN/c12-10-5-9(6-14-7-10)8-1-3-11(13)4-2-8/h1-7H

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 1765-93-1 4-fluoroboronic acid 

Relevant articles and documents

Fine-tuning the selectivity of aldosterone synthase inhibitors: Structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1- ij ]quinolin-4-one derivatives

Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis. Among these, ethyl-substituted 3 possesses high selectivity against CYP1A2. Rigidification of 3 by incorporation of the ethyl group into a 5- or 6-membered ring affords compounds with a pyrroloquinolinone or pyridoquinolinone molecular scaffold (e.g., 4 and 5). It was found that these molecules are even more potent and selective CYP11B2 inhibitors than their corresponding open-chain analogues. Moreover, pyrroloquinolinone 4 exhibits no inhibition of the six most important hepatic CYP enzymes as well as a bioavailability in the range of the marketed drug fadrozole. The SAR studies disclose that subtle changes in the heterocyclic moiety are responsible for either a strong or a weak inhibition of the highly homologous 11-hydroxylase (CYP11B1). These results are not only important for fine-tuning the selectivity of CYP11B2 inhibitors but also for the development of selective CYP11B1 inhibitors that are of interest for the treatment of Cushing's syndrome and metabolic syndrome.

DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS

The present invention relates to a compounds of formula (I): wherein A, B, D, E and F are defined herein; that are useful in treating central nervous system (CNS) diseases, disorders and conditions, such as but not limited to nicotine addiction, schizophr